(Q33408889)

26 July 2017

title

Panobinostat in lymphoid and myeloid malignancies (English)

1 reference

26 July 2017

Amit Khot

1

0 references

author name string

Michael Dickinson

series ordinal

2

1 reference

26 July 2017

H Miles Prince

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

3 July 2013

1 reference

Expert Opinion on Investigational Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

22

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

1211-1223

1 reference

26 July 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Predicting survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Panobinostat for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Relapsed/refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

A phase 2 study of vorinostat in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Epigenetic therapy of lymphoma using histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

Targeting epigenetic readers in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.815165

10.1517/13543784.2013.815165

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference